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Translational relevance 
Our unique study using patient samples, humanised mouse models of bone 
metastasis, genetic manipulation of breast cancer cells and in vitro modelling 
demonstrate multiple roles for tumor cell-derived IL-1B in the process of breast 
cancer bone metastasis. These data are hugely significant to clinicians and basic 
scientists alike: Our results suggest that tumor-cell derived IL-1B can be used as a 
biomarker to predict patients who are likely to experience breast cancer relapse and 
metastasis. In addition, we provide evidence that targeting IL-1B signalling with the 
anti IL-1B antibody, Canakinumab, or the IL-1R antagonist, Anakinra, may provide 
therapeutic benefit to patients with tumors that express IL-1B specifically by the 
malignant cells. Future research will establish if tumor cell derived IL-1B can be used 
as a biomarker and therapeutic target for other cancers that metastasise to bone. 
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Abstract 
 
Background: Breast cancer bone metastases are incurable highlighting the need for 
new therapeutic targets. After colonizing bone, breast cancer cells remain dormant, 
until signals from the microenvironment stimulate outgrowth into overt metastases. 
Here we show that endogenous production of IL-1B by tumor cells drives metastasis 
and growth in bone. 
 
Methods: Tumor/stromal IL-B and IL-1R1 expression was assessed in patient 
samples and effects of the IL-1R antagonist, Anakinra or the IL-1B antibody 
Canakinumab on tumor growth and spontaneous metastasis were measured in a 
humanized mouse model of breast cancer bone metastasis. Effects of tumor cell-
derived IL-1B on bone colonisation and parameters associated with metastasis were 
measured in MDA-MB-231, MCF7 and T47D cells transfected with IL-1B/control.  
 
Results: In tissue samples from >1300 patients with stage II/III breast cancer, IL-1B 
in tumor cells correlated with relapse in bone (hazard ratio 1.85; 95% CI 1.05-3.26; 
P=0.02) and other sites (hazard ratio 2.09; 95% CI 1.26-3.48; P=0.0016). In a 
humanized model of spontaneous breast cancer metastasis to bone, Anakinra or 
Canakinumab reduced metastasis and reduced the number of tumor cells shed into 
the circulation. Production of IL-1B by tumor cells promoted EMT (altered E-
Cadherin, N-Cadherin and G-Catenin), invasion, migration and bone colonisation.  
Contact between tumor and osteoblasts or bone marrow cells increased IL-1B 
secretion from all three cell types. IL-1B alone did not stimulate tumor cell 
proliferation. Instead, IL-1B caused expansion of the bone metastatic niche leading 
to tumor proliferation. 
Conclusion: Pharmacological inhibition of IL-1B has potential as a novel treatment 
for breast cancer metastasis. 
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Introduction 
There are over 508,000 deaths annually from breast cancer worldwide with around 
75% of patients with advanced breast cancer developing bone metastasis (1). 
Although bone metastases are more common in oestrogen receptor (ER)+ve disease, 
ER ±ve tumors also metastasise to the skeleton. Once breast cancer has spread to 
the bones, the disease is incurable and existing treatments can only slow 
progression. Median survival is 2-3 years following diagnosis of skeletal involvement, 
hence new therapeutic approaches are needed to improve outcome for these poor 
prognosis patients. (2). Identification of molecules that drive tumor growth in bone will 
provide targets for developing such urgently needed novel therapies. Elevated tumor 
IL-1B is associated with poor prognosis in a variety of cancers, including breast, 
prostate, colon, and lung (3). Importantly, recent data have demonstrated 
significantly reduced incidence of lung cancer in patients with atherosclerosis who 
have received the anti-Interleukin IB (IL-1B) antibody Canakinumab (4). However, 
the mechanisms by which IL-1B promotes cancer development and metastatic 
progression remains to be established. 
We have recently identified a direct link between IL-1B and breast cancer bone 
metastasis (2): In a small study using a tissue array of 150 human primary breast 
cancer samples from patients with stage II/III breast cancer with a median follow up 
of 84 months (AZURE trial (5)) we found a significant correlation between IL-1B 
expression and subsequent development of bone metastases (P < 0.0001) (2). We 
have confirmed this link between IL-1B and breast cancer bone metastasis in animal 
models by demonstrating increased IL-1B expression in breast cancer cells that have 
been passaged In vivo to make them home to bone when injected directly into the 
blood stream (2). Our previously published data, therefore, suggest that IL-1B 
expressed by breast cancer cells makes them more aggressive and may play a role 
in the initiation of the metastatic process.  IL-1B also appears to play a crucial role in 
the development of overt metastases from disseminated tumor cells within the bone 
environment: Inhibiting IL-1B binding to Interleukin 1 receptor 1 (IL-1R1) inhibits 
metastases from tumor cells disseminated in bone and reduces growth of 
established bone metastasis in vivo (6). These findings suggest that IL-1B also plays 
a role in the later stages of bone metastasis development in which breast cancer 
cells emerge from dormancy and proliferate in the bone microenvironment.  
In the current study we have utilised in vitro and in vivo model systems in conjunction 
with patient samples to identify how tumor cell derived IL-1B drives the different 
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stages of breast cancer progression and bone metastasis. We have also investigated 
the effect of targeting the IL-1B pathway using compounds that are Food and Drug 
Administration (FDA) approved for the treatment of rheumatoid arthritis, using the 
anti-human IL-1B antibody Canakinumab (Canakinumab and IL-1R antagonist, 
Anakinra .LQHUHW, on in vivo models of spontaneous human breast cancer 
metastasis to human bone implants, in order to establish the potential of repurposing 
these drugs for the treatment of breast cancer bone metastasis. 
Materials and Methods 
Experimental models and subject details 
Animals 
Experiments using human bone grafts were carried out in 10-week old female NOD 
SCID mice, IL-1B/IL-1R1 overexpression bone homing experiments used 6-8 week 
old female BALB/c nude mice, effects of IL-1B on the bone microenvironment used 
10-week old female C57BL/6 mice (Charles River, Kent UK), IL-1R1 KO or IL-1B KO 
mice (7). Mice were maintained on a 12h: 12h light/dark cycle with free access to 
food and water. Experiments were carried out with home office approval under 
project licence 40/3531, University of Sheffield, UK. 
Cell lines 
Human breast cancer MDA-MB-231-Luc2-TdTomato (Calliper Life Sciences, 
Manchester UK), MDA-MB-231 (parental) MCF7, T47D  (European Collection of 
Authenticated Cell Cultures (ECACC)), MDA-MB-231 IV (2) as well as E0771 mouse 
mammary cancer cells (ECACC) bone marrow HS5 (ECACC) and human primary 
PRE-osteoblasts, OB1, (gift from Dr Marianna de Julio) were cultured in DMEM + 
10% FCS (Gibco, Invitrogen, Paisley, UK).  Cell lines purchased from commercial 
sources have been authenticated in house using short tandem repeat analysis of 10 
loci. All cell lines were cultured in a humidified incubator under 5% C02 and used at 
low passage >20 within 24 months of last date of authenification. 
Patient samples 
All human samples were obtained following written informed consent from patients 
and studies were conducted in accordance with the Declaration of Helsinki. IL-1B 
and IL-1R1 expression was assessed on tissue microarrays (TMA) containing 
primary breast tumor cores taken from 1,300 patients included in the clinical trial, 
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AZURE (Sponsored by the University of Sheffield and approved as a United 
Kingdom national trial by the Clinical Trials Committee; controlled trials number 
ISRCTN79831382) (5). These samples were taken from patients with stage II and III 
breast cancer, pre-treatment between 2003 and 2006, without evidence of 
metastasis. Patients were subsequently randomised to standard adjuvant therapy 
with or without the addition of zoledronic acid for 5 years and followed up for 10 
years (5). The TMAs were stained for IL-1B and scored blindly, under the guidance 
of histopathologist, Prof. Andrew Hanby, for IL-1B/IL-1R1 in the tumor cells or in the 
associated stroma. Tumor cell or stromal IL-1B or IL-1R1 was then linked to disease 
recurrence (any site) or disease recurrence specifically in bone (+/- other sites).  
 
Human bone 
Human femoral bone was isolated from 60-70-year-old female patients who had 
undergone total hip replacement surgery for rheumatoid arthritis. Patients who had 
previous exposure to anti-resorptive drugs or anti-IL-1 treatments were excluded. All 
patients provided written, informed consent prior to participation in this study which 
was carried out in accordance with the ethical guidelines set out in the Declaration of 
Helsinki. Human bone samples were collected under Human Tissue Act (HTA) 
licence 12182, Sheffield Musculoskeletal Bio bank, University of Sheffield UK. 
Trabecular bone cores were prepared using an Isomet 4000 Precision saw (Buehler) 
with Precision diamond wafering blade (Buehler). 5mm diameter discs were 
subsequently cut using a bone trephine before storing in sterile PBS at ambient 
temperature. 
 
Method details 
Transfection of tumor cells:  
Human MDA-MB-231, MCF 7 and T47D cells were stably transfected to over 
express IL-1B or IL-1R1 using plasmid DNA purified from competent E.Coli that have 
been transduced with an ORF plasmid containing human IL-1B or IL-1R1 (Accession 
numbers NM_000576 and NM_0008777.2 respectively) with a C terminal GFP tag 
(OriGene Technologies Inc. Rockville MD). Plasmid DNA purification was performed 
using a 3XUH/LQN+iPure Plasmid Miniprep Kit (ThemoFisher) and DNA quantified 
by UV spectroscopy before being introduced into human cells with the aid of 
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Lipofectamine II (ThermoFisher).  Control cells were transfected with DNA isolated 
from the same plasmid without IL-1B or IL-1R1 coding sequences. 
In vitro studies 
In vitro studies were carried out with and without addition of 0-5ng/ml recombinant IL-
1B (R&D systems, Wiesbaden, Germany) +/- 50uM IL-1Ra (Amgen, Cambridge, UK). 
Cells were transferred into fresh media with 10% or 1% Foetal Calf Serum (FCS).  
Cell proliferation was monitored every 24h for up to 120h by manual cell counting 
using a 1/4002 haemocytometer (Hawkley, Lancing UK) or over a 72h period using 
an Xcelligence RTCA DP Instrument (Acea Biosciences inc). Tumor cell invasion 
was assessed using 6mm transwell plates with an 8uM pore size (Costar; Corning 
Incorporated, NY, USA) +/- basement membrane (20% Matrigel: Invitrogen). Tumor 
cells were seeded into the inner chamber at a density of 2.5X105 for parental and 
MDA-MB-231 derivatives and 5X105 for T47D in DMEM + 1% FCS and 5X105 OB1 
osteoblast cells supplemented with 5% FCS were added to the outer chamber. Cells 
were removed from the top surface of the membrane 24 and 48h after seeding and 
cells that had invaded through the pores were stained with haematoxylin and eosin 
before being imaged on a Leica DM7900 light microscope and manually counted.  
Migration of cells was investigated by analysing wound closure: Cells were seeded 
onto 0.2% gelatine in 6-well tissue culture plates (Costar; corning incorporated); once 
confluent, 10ug/ml mitomycin C was added to inhibit cell proliferation and a 50uM 
scratch made across the monolayer. The percentage of wound closure was 
measured at 24 and 48h using a CTR7000 inverted microscope and LAS-AF v2.1.1 
software (Leica Applications Suite; Leica Microsystems, Wetzlar, Germany).  All 
proliferation, invasion and migration experiments were repeated using the 
Xcelligence RTCA DP instrument and RCTA Software (Acea, Biosystems inc). 
For co-culture studies with human bone 5X105 MDA-MB-231 or T47D cells were 
seeded onto tissue culture plastic or into 0.5cm3 human bone discs for 24h. Media 
was removed and analysed for concentration of IL-1B in the media by ELISA. For co-
culture with HS5 or OB1 cells, 1X105 MDA-MB-231 or T47D cells were cultured onto 
plastic along with 2X105 HS5 or OB1 cells. Cells were sorted by FACS (as described 
below) 24h later counted and lysed for analysis of IL-1B concentration. Cells were 
collected, sorted and counted every 24h for 120h. 
In vivo studies 
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To model human breast cancer metastasis to human bone implants; two-human 
bone discs were implanted subcutaneously into 10-week old female NOD SCID mice 
(n=10/group) under isofluorane anaesthetic. Mice received an injection of 0.003mg 
vetergesic and Septrin was added to the drinking water for 1-week following bone 
implantation. Mice were left for 4-weeks before injecting 1X105 MDA-MB-231 Luc2-
TdTomato, MCF7 Luc2 or T47D Luc2 cells in 20% Martigel/79% PBS/1% toluene 
blue into the two hind mammary fat pads. Primary tumor growth and development of 
metastases was monitored weekly using an IVIS (Luminol) system (Caliper Life 
Sciences) following sub-cutaneous injection of 30mg/ml D luciferin (Invitrogen). On 
termination of experiments mammary tumors, circulating tumor cells, serum and 
bone metastases were resected.  RNA was processed for downstream analysis by 
real time PCR , cell lysates were taken for protein analysis and whole tissue for 
histology as previously described (2,8). 
For therapeutic studies in NOD SCID mice, placebo (control), 1mg/mg/day IL-1Ra or 
10mg/kg/14 days Canakinumab (Novartis Pharmaceuticals) were administered 
subcutaneously starting 7 days after injection of tumor cells. In BALB/c mice and 
C57BL/6 mice 1mg/kg/day IL-1Ra was administered for 21 or 31 days or 10mg/kg 
Canakinumab was administered as a single sub-cutaneous injection. Tumor cells, 
serum, and bone were subsequently resected for downstream analysis. 
Bone metastases were investigated following injection of 5X105 MDA-MB-231 GFP 
(control), MDA-MB-231 IV, MDA-MB-231 IL-1B+ or MDA-MB-231 IL-1R1+ cells into 
the lateral tail vein of 6-8 week old female BALB/c nude mice (n=12/group) or 
following intra-ductal injection of E0771 1.25X105 cells into the 4th and 9th mammary 
ducts of IL-1B-KO or fl/fl control mice. Tumor growth in bones and lungs was 
monitored weekly by GFP imaging in live animals. Mice were culled 28 days after 
tumor cell injection at which point hind limbs, lungs and serum were resected and 
processed for uCT, histology and ELISA analysis of bone turnover markers and 
circulating cytokines as previously described (6). 
Isolation of circulating tumor cells 
Whole blood was centrifuged at 10,000g for 5 minutes and the serum removed for 
ELISA assays. The cell pellet was re-suspended in 5ml of FSM lysis solution (Sigma-
Aldrich, Pool, UK) to lyse red blood cells. Remaining cells were re-pelleted, washed 
3-times in PBS and re-suspended in a solution of PBS/10% FCS. Samples from 10-
mice per group were pooled prior to isolation of TdTomato positive tumor cells using 
a MoFlow High performance cell sorter (Beckman Coulter, Cambridge UK) with the 
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470nM laser line from a Coherent I-90C tenable argon ion (Coherent, Santa Clara, 
CA). For gene expression analysis: TdTomato fluorescence was detected by a 
555LP dichroic long pass and a 580/30nm band pass filter. Acquisition and analysis 
of cells was performed using Summit 4.3 software. Following sorting cells were 
immediately placed in RNA protect cell reagent (Ambion, Paisley, Renfrew, UK) and 
stored at -800C before RNA extraction. For counting numbers of circulating tumor 
cells: TdTomato fluorescence was detected using a 561 nm laser and an YL1-A filter 
(585/16 emission filter). Acquisition and analysis of cells was performed using Attune 
NxT software. 
Microcomputed tomography (uCT) imaging:  
ȝ&7 DQDO\VLV ZDV FDUULHG RXW XVLQJ D 6N\VFDQ  [-ray-FRPSXWHG ȝ&7 VFDQQHU
(Skyscan, Aartselar, Belgium) equipped with an x-ray tube (voltage, 49kV; current, 
200uA) and a 0.5-mm aluminium filter. Pixel size was set to 5.86 Pm and scanning 
initiated from the top of the proximal tibia as previously described (9,10). 
Bone histology and measurement of tumor volume:  
Bone tumor areas were measured on 3, non-serial, Haematoxylin and Eosin (H&E) 
stained, 5PM histological sections of decalcified tibiae per mouse using a Leica  
RMRB upright microscope and Osteomeasure software (Osteometrics inc. Dakota, 
USA) and a computerised image analysis system  (9).  
Western blotting: 
Protein was extracted using a mammalian cell lysis kit (Sigma-Aldrich, Poole, UK). 
30ug of protein was run on 4-15% precast polyacrylamide gels (BioRad, Watford, 
UK) and transferred onto an imibilon-P nitrocellulose membrane (Millipore). 
Nonspecific binding was blocked with 1% casein (Vector laboratories) before 
incubation with rabbit monoclonal antibodies to human N-Cadherin (D4R1H) 1:1000,  
E-Cadherin (24E10) 1:500 or Gamma Catenin (2303) 1:500 (Cell signalling) or 
mouse monoclonal GAPDH  (ab8245) 1:1000 (AbCam, Cambridge UK) for 16h at 40 
C. Secondary antibodies were anti-rabbit or anti-mouse horse radish peroxidase 
(HRP; 1:15,000) and HRP was detected with the Supersignal chemiluminescence 
detection kit (Pierce). Band quantification was carried out using Quantity Once 
software (BioRad) and normalised to GAPDH. 
Gene analysis 
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Total RNA was extracted using TRI reagent before being reverse transcribed into 
cDNA using High-capacity RNA-to cDNA kit (Thermofisher). Relative mRNA 
expression of IL-1B (Hs02786624), IL-1R1 (Hs00174097), Caspase 1 (Hs00354836), 
IL1RN (Hs00893626), JUP (Hs00984034), N-Cadherin (Hs01566408) and E-
Cadherin (Hs1013933) were compared with the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; Hs02786624) and assessed using an ABI 
7900 PCR System (Perkin Elmer, Foster City, CA) and Taqman universal master mix 
(All reagents were purchased from Applied Biosystems via Thermofisher, UK)). Fold 
change in gene expression between treatment groups was analysed by inserting CT 
values into Data Assist V3.01 software (Applied Biosystems) and changes in gene 
H[SUHVVLRQZHUHRQO\DQDO\VHGIRUJHQHVZLWKD&7YDOXHRI 
Immunohistochemistry 
Immunohistochemistry for the endothelial cells was performed using a mouse 
specific anti CD34 antibody (MCA1825-GA: 1:50 dilution; Serotec, Oxford, UK) 
followed by a biotin conjugated anti-rat secondary antibody (E0467 1:200) as 
previously described (Nutter et al, 2014). Two-non-serial sections per sample were 
scored prior to statistical analysis.TMAs were stained for IL-1B (ab2105, 1:200 
dilution, Abcam) and IL-1R1 (ab59995, 1:25 dilution, Abcam) and scored blindly, , for 
IL-1B/IL-1R1 in the tumor cells or in the associated stroma. Tumor or stromal IL-1B 
or IL-1R1 was then linked to disease recurrence (any site) or disease recurrence 
specifically in bone (+/- other sites). 
Biochemical analysis 
Serum concentrations of TRACP-5b and P1NP were measured using commercially 
available ELISA kits: Mouse TRAP $VVD\ DQG 5DWMouse P1NP competitive 
immunoassay kit (immunodiagnostic systems). Concentrations of IL-1B were 
analysed in mouse bone marrow, human breast cancer cells and in co-culture 
systems using anti-mouse or anti-human Quantikine ELISA kits, as appropriate (R&D 
systems, Abingdon, UK) and PDQXIDFWXUHU¶V instructions. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
For experiments using non-clinical material group wise comparisons were carried out 
using one-way independent ANOVA with 7XUNH\¶V multiple comparison test using 
GraphPad PRISM® software version 6.0. Statistical significance was defined as P 
less than or equal to 0.05. A Cox proportional hazards model, using the statistical 
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software, was used to investigate the effect of Il-1B in a multivariate model including 
number of involved lymph nodes, tumor grade, oestrogen-receptor status, tumor 
stage and type of planned systemic therapy (endocrine therapy, chemotherapy or 
both).   Statistical significance was determined using 2-sided p-values <.05.   
 
Results 
The IL-1B pathway is upregulated during the process of human breast cancer 
metastasis to human bone.  
A mouse model of spontaneous human breast cancer metastasis to human bone 
implants was utilised to investigate how the IL-1B pathway changes through the 
different stages of metastasis (11); supplementary figure 1).  Using this model, the 
expression levels of genes associated with the IL-1B pathway increased in a 
stepwise manner at each stage of the metastatic process in both triple negative 
(MDA-MB-231) and ER+ve (T47D) breast cancer cells: Genes associated with the IL-
1B signalling pathway (IL-1B, IL-1R1, Caspase 1 and IL-1R antagonist (IL-1Ra)) 
were expressed at very low levels in both MDA-MB-231 and T47D cells grown in 
vitro and expression of these genes were not altered in primary mammary tumors 
from the same cells that did not metastasise in vivo (figure 1a). 
IL-1B, IL-1R1 and Caspase 1 were all significantly increased in mammary tumors 
that subsequently metastasised to human bone, compared with those that did not 
metastasise (P < 0.01 for both cell lines), leading to activation of IL-1B signalling as 
shown by ELISA for active 17KD IL-1B (figure 1b; supplementary figure 2). IL-1B 
gene expression increased in circulating tumor cells compared with metastatic 
mammary tumors (P < 0.01 for both cell lines). IL-1B (P < 0.001), IL-1R1 (P < 0.01), 
Caspase 1 (P < 0.001) and IL-1Ra (P < 0.01) were further increased in tumor cells 
isolated from metastases in human bone compared with their corresponding 
mammary tumors, leading to further production of IL-1B protein (figure 1; 
supplementary figure 2). These data suggest that IL-1B signalling may promote both 
initiation of metastasis from the primary site, as well as development of breast cancer 
metastases in bone.  
Tumor-derived IL-1B promotes EMT and breast cancer metastasis. 
Expression levels of genes associated with tumor cell adhesion and epithelial to 
mesenchymal transition (EMT) were significantly altered in primary tumors that 
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metastasised to bone compared with tumors that did not metastasise (figure 1c).  We 
therefore generated IL-1B overexpressing cells (MDA-MB-231-IL-1B+, T47D-IL-1B+ 
and MCF7-IL-1B+) to investigate whether tumor cell-derived IL-1B is responsible for 
inducing EMT and metastasis to bone.  Compared to the corresponding controls, all 
IL-1B+ cell lines demonstrated increased EMT, exhibiting morphological changes 
from an epithelial to mesenchymal phenotype (figure 2a) as well as reduced 
proliferation (figure 2b), reduced expression of E-cadherin, and Junction plakoglobin 
(JUP) and increased expression of N Cadherin gene and protein (figure 2c and d). 
Wound closure (p < 0.0001 in MDA-MB-231-IL-1B+; p < 0.001 MCF7-IL-1B+ and 
T47D-IL-1B+ (figure 2e)), migration and invasion through matrigel towards 
osteoblasts (p < 0.0001 in MDA-MB-231-IL-1B+; p < 0.001 MCF7-IL-1B+ and T47D-
IL-1B+ (figure 2g)) were increased in tumor cells with elevated IL-1B signalling (IL-
1B+) compared with their respective controls. These data imply that endogenous 
production of IL-1B by tumor cells promotes EMT and promotes a more invasive and 
migratory phenotype. 
Inhibition of IL-1B signalling reduces spontaneous metastasis to human bone. 
As tumor cell-derived IL-1B appeared to be promoting onset of metastasis through 
induction of EMT, we next investigated the effects of inhibiting IL-1B signalling with 
an IL-1 receptor antagonist (IL-1Ra) or the human antibody against IL-1B, 
Canakinumab, on primary tumor growth and spontaneous metastasis to human bone 
implants: Daily administration of IL-1Ra had no effect on growth of MDA-Td cells in 
the mammary fat pad, whereas fortnightly administration of Canakinumab resulted in 
significantly increased growth of the primary tumor (P = 0.003 compared with 
placebo and 0.006 compared with IL-1Ra; figure 3a). In contrast, both IL-1Ra and 
Canakinumab reduced metastasis to human bone; metastases were detected in 
human bone implants from 7/10 control mice, 4/10 IL-1Ra treated mice and 1/10 
Canakinumab treated mice. Bone metastases isolated from IL-1Ra and 
Canakinumab treatment groups were also smaller than those detected in the control 
group (figure 3b) suggesting that specific inhibition of human IL-1B produced by the 
tumor cells reduces metastasis. Numbers of cells detected in the circulation of mice 
treated with Canakinumab or IL-1Ra were significantly lower than those detected in 
the placebo treated group: Only 3 tumor cells/ml were counted in whole blood from 
mice treated with either Canakinumab or IL-1Ra compared to 108 tumor cells/ml 
counted in blood from placebo treated mice (supplementary figure 4). These data 
suggest that inhibition of IL-1 signalling prevents tumor cells from being shed from 
the primary site into the circulation. 
 13 
Tumor cell derived IL-1B promotes bone homing and colonisation of breast 
cancer cells. 
To assess whether metastasis was driven by IL-1B from tumor cells or from the 
microenvironment, we used genetic manipulation to increase expression of IL-1B in 
tumor cells alongside a mouse model from which IL-1B has been genetically knocked 
out (IL-1B KO).  Injection of breast cancer cells into the tail vein of mice usually 
results in lung metastasis due to tumor cells becoming trapped in the lung capillaries. 
We have previously shown that breast cancer cells that preferentially home to the 
bone microenvironment following intra-venous injection express high levels of IL-1B, 
suggesting that this cytokine may be involved in tissue-specific homing of breast 
cancer cells to bone (2). In the current study, intra-venous injection of MDA-MB-231-
IL-1B+ cells into BALB/c nude mice resulted in significantly increased number of 
animals developing bone metastasis (75%) compared to animals injected with control 
cells (12%) (P < 0.001; figure 3c). MDA-MB-231-IL-1B+ tumors caused development 
of significantly larger osteolytic lesions in mouse bone compared with control cells (P 
= 0.03; figure 3d) There was a non-significant numerical reduction in lung metastases 
in mice injected with MDA-MB-231-IL-1B+ cells compared with control cells (P = 
0.16; figure 3e). Removal of IL-1B from the microenvironment did not alter 
metastasis: Injection of E0771 cells into the mammary ducts of IL-1B KO and control 
(IL-1B fl/fl) mice resulted in metastasis in bone and lung (figure 3f). These data 
strengthen the hypothesis that endogenous IL-1B rather than Il-1B from the 
microenvironment promotes tumor cell homing and development of bone 
metastases..  
Tumor cell-bone cell interactions further induce IL-1B and promote 
development of overt metastases. 
Using assays specifically designed to amplify human mRNA, gene analysis data from 
our mouse model of human breast cancer metastasis to human bone implants 
suggested that the IL-1B pathway was further increased when breast cancer cells 
are growing in the bone environment compared with metastatic cells in the primary 
site or in the circulation (figure 1a). We therefore investigated how IL-1B production 
changes when tumor cells come into contact with bone cells and how IL-1B alters the 
bone microenvironment to affect tumor growth (figure 4). Culture of human breast 
cancer cells into pieces of whole human bone for 48h results in increased secretion 
of IL-1B into the media (P < 0.0001 for MDA-MB-231 and T47D cells; figure 5a). Co-
culture with human HS5 bone marrow cells revealed that increased IL-1B 
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concentrations originated from both the cancer cells (P < 0.001) and bone marrow 
cells (P < 0.001), with IL-1B from tumor cells increasing ~1000 fold and IL-1B from 
HS5 cells increasing ~100 fold following co-culture (figure 4b).  
It is hypothesised that when metastatic tumor cells arrive in the bone they either 
reside in the vascular niche from which they may be stimulated to form overt 
metastasis through expansion of the associated vasculature or they are deposited in 
the bone marrow from which they home to the osteoblastic niche and become 
dormant (12-15). Stimulation of osteoblast proliferation is thought to stimulate 
proliferation of previously dormant tumor cells within this niche, thereby promoting 
onset of overt metastases (8,12,16). We therefore investigated the effects of 
exogenous IL-1B and IL-1B from tumor cells on proliferation of tumor cells, 
osteoblasts and bone marrow cells as well as the effects of IL-1B on CD34+ blood 
vessels: Co-culture of HS5 bone marrow or OB1 primary osteoblast cells with breast 
cancer cells caused increased proliferation of all cell types (P< 0.001 for HS5, MDA-
MB-231 or T47D, figure 4c) (P < 0.001 for OB1, MDA-MB-231 or T47D, figure 4d). 
Furthermore, administration of IL-1B increased proliferation of HS5 (figure 5b) or 
OB1 (figure 5c) cells but not breast cancer cells (figure 5a), suggesting that tumor 
cell-bone cell interactions promote production of IL-1B that can drive expansion of 
the niche and stimulate the formation of overt metastases.  
IL-1B signalling was also found to have significant effects on the bone 
microvasculature: Preventing IL-1B signalling in bone by knocking out IL-1R1, 
pharmacological blockade of IL-1R with IL-1Ra or reducing circulating concentrations 
by administration of an anti-IL-1B antibody reduced the average length of CD34+ 
blood vessels in trabecular bone, where tumor colonisation takes place (Wang et al 
2014) (P < 0.01 for IL-1Ra and anti-IL-1B treated mice) (figure 5c). These findings 
were confirmed by endomeucin staining which showed decreased numbers of blood 
vessels and blood vessels length in bone when IL-1B signalling was disrupted (data 
not shown). ELISA analysis for endothelin 1 and VEGF showed reduced 
concentrations of both of these endothelial cell markers in the bone marrow in IL-1R1 
KO mice (P < 0.001 endothelin 1; P < 0.001 VEGF), mice and mice treated with IL-
1R antagonist (P < 0.01 endothlin 1; P < 0.01 VEGF) or Canakinumab (P < 0.01 
endothelin 1; P < 0.001 VEGF) compared with control (supplementary figure 5). 
These data suggest that tumor cell-bone cell associated increases in IL-1B and high 
levels of IL-1B in tumor cells may also promote angiogenesis, further stimulating 
metastases. 
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IL-1B promotes osteoclast and osteoblast activity in vivo. 
High levels of bone turnover are associated with increased bone metastasis and It is 
hypothesised that interactions between tumor cells and bone cells instigate a vicious 
cycle whereby tumor cells stimulate osteoclast activity and bone resorption. 
Subsequent release of growth factors from the bone then stimulates growth of tumor 
cells (17). Bone turnover is primarily regulated by activity of osteoclast and 
osteoblasts, we therefore investigated the effects of IL-1B signalling on activity of 
these cell types (supplementary figure 6). Mice that are globally deficient in IL-1R1 
have significantly increased trabecular bone volume (P < 0.0001; Supplementary 
figure 6a), decreased osteoclast activity (P<0.0001) and decreased osteoblast 
activity (P<0.0001) compared with control (IL-1R1 fl/fl) mice (supplementary figure 
6b). Disrupting IL-1B signalling by daily injection with 1mg/kg IL-1Ra or 
Canakinumab every 14 days for 8 weeks in mice bearing human bone implants also 
led to reduced osteoclast (P<0.001 for IL-1Ra and P< 0.01 for Canakinumab) and 
osteoblast (P<0.0001 for IL-1Ra and P<0.001 for Canakinumab) activity 
(supplementary figure 6c). Interestingly, growing tumor cells that express high levels 
of IL-1B in mouse bone (MDA-MB-231-IL-1B+) resulted in increased osteoclast 
activity (P< 0.01) compared with control cells growing in the same environment but 
osteoblast activity was not altered (supplementary figure 6d). These data indicate 
that IL-1B has profound effects on osteoclast and osteoblast activity in vivo and 
inhibiting bone turnover through anti-IL-1 treatments may be a mechanism by which 
this therapeutic approach reduces bone metastases. 
Tumor cell derived IL-1B predicts future breast cancer relapse in bone and 
other organs in clinical samples 
To establish the relevance of our laboratory findings in a clinical setting we 
investigated the correlation between IL-1B and its receptor IL-1R1 in patient samples. 
1189 primary tumor samples (not previously included in our hypothesis generating 
study (2)) from patients with stage II/III breast cancer with no evidence of metastasis 
included in the randomized phase III  AZURE trial evaluating standard adjuvant 
systemic therapy with or without the bisphosphonate, zoledronic acid  (18) were 
stained for the 17KD form of active IL-1B or IL-1R1. Samples were scored separately 
for expression of IL-1B or IL-1R1 in the tumor cells and the tumor associated stroma. 
Patents were followed up for 10-years and correlation between IL-1B/IL-1R1 
expression and distant recurrence or relapse in bone assessed using a Cox 
proportionate hazards model. IL-1B in tumor cells strongly correlated with distant 
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recurrence at any site (P = 0.0016: Hazard ratio 2.09; CI 1.26-3.48) or recurrence in 
bone at any time (P = 0.0387: Hazard ratio 1.85: CI 1.05-3.26) (figure 6). IL-1B in the 
stroma did not correlate with future relapse nor did IL-1R1 in the tumor or the stroma 
(supplementary table 1). Patients who had IL-1B in their tumor cells and IL-1R1 in 
the tumor associated stroma were more likely to experience future relapse at a 
distant site (P = 0.042), compared to patients who did not have IL-1B in their tumor 
cells, indicating that tumor-derived IL-1B may not only promote metastasis directly 
but also interact with IL-1R1 in the stroma to promote this process.  
Bone metastases are more prevalent in ER+ve breast cancer whereas, ER-ve 
tumors are more likely to metastasise to lung. To investigate the prognostic value of 
IL-1B in different patient sub-groups, we analysed the correlation between IL-1B in 
tumor cells and future relapse in bone or any tissue for ER+ve and ER-ve tumors 
separately.  The link between IL-1B and bone metastasis was significantly stronger in 
ER+ve tumors (p= 0.02: Hazard ratio 2.09: CI 1.11-3.83) than in ER-ve tumors 
(p=0.65: Hazard ratio 0.71: CI 0.16-3.09). However, no differences were observed 
between IL-1B expression in tumor cells and recurrence at any site between patients 
with ER+ve and ER-ve disease. Both groups showed a strong positive correlation 
with IL-1B in tumor cells and subsequent distal metastases  (Hazard ratios 2.05 for 
ER+ve and 2.21 for ER-ve, respectively). Taken together these data suggest that 
expression of IL-1B by tumor cells is predictive of future development of metastases. 
 
Discussion 
Our data show that endogenous production of IL-1B by breast cancer cells increases 
their metastatic potential in in vitro and in vivo models and is associated with 
increased bone recurrence in breast cancer patients. Increased IL-1B production was 
seen in ER+ve and ER-ve breast cancer cells that spontaneously metastasised to 
human bone implants in vivo compared with non-metastatic breast cancer cells 
(figure1). The same link between IL-1B and metastasis was made in primary tumor 
samples from patients with stage II and III breast cancer enrolled in the AZURE study 
(18) that experienced disease recurrence during a 10 year follow-up period. In a 
previous study we have shown a link between IL-1B in primary tumor samples and 
subsequent relapse in bone from 150 samples over a 5-year follow up period (2). In 
the current study we were interested in assessing whether this correlation was 
associated specifically with IL-1B produced by tumor cells or IL-1B from the tumor 
environment. We therefore used an antibody to the active 17KD form of IL-1B and 
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scored IL-1B in tumor cells and the stoma separately. Interestingly, expression of IL-
1B in tumor cells correlated with both relapse in bone and relapse at any site 
indicating that presence of this molecule is likely to play a role in metastasis in 
general.  No correlation was observed between IL-1B in the tumor microenvironment 
or IL-1R1 expression, indicating that relapse in distant organs is influenced by tumor-
cell derived IL-1B. Further analysis revealed that correlation between IL-1B 
expression in tumor cells and subsequent recurrence specifically in bone is highly 
significant in patients with ER+ve tumors (P < 0.02), but this correlation was not 
observed in patients with ER-ve disease. In contrast, expression of IL-1B in primary 
tumor samples was predictive of distal recurrence to any site in both ER+ve and ER-
ve disease. Bone metastases are more common from ER+ve tumors and in our data 
set of 1189 patients bone metastasis developed from 181 ER+ve tumors and 29 ER-
ve tumors. It is therefore likely that lack of correlation between IL-1B and bone 
metastasis, observed in the ER-ve group, is due to the small number of patients in 
this group providing insufficient power for these calculations. A larger set of patients 
is required to test this hypothesis  
In agreement with the clinical data, genetic manipulation of breast cancer cells to 
artificially overexpress IL-1B increased their migration and invasion capacities in vitro 
(figure 2). Furthermore, inhibition of IL-1B signalling with the human specific anti-IL-
1B antibody Canakinumab or inhibition of the IL-1R reduced the number of breast 
cancer cells shed into the circulation and reduced metastases in human bone 
implants (figure 3). Interestingly, administration of Canakinumab significantly 
increased growth of MDA-Td cells in the mammary fat pad whereas the IL-1Ra had 
no effect. Daily administration of IL-1Ra has previously been shown to reduce sub-
cutaneous tumor growth of MDA-IV and MCF7 cells (6) as well as causing a small 
reduction in growth of 4T1 cells injected into the mammary fat pad (6,19). Data from 
both of these studies suggest that inhibition of IL-1 does not exert direct cytotoxic 
effects on tumor cells, but inhibits tumor cell proliferation possibly by inhibiting the 
formation of new blood vessels (6,19). In the current study both control and IL-1Ra 
treated tumors were small (>0.3mm3) when mice were culled and therefore it is likely 
that tumors were too small for differences in growth to be detected (figure 3a). Until 
now there have been no reports on the effects of Canakinumab on tumor growth and 
metastasis. Data from patients with atherosclerosis who have received Canakinumab 
demonstrate significantly reduced incidences of lung cancer, however, the study was 
not designed to investigate effects on existing cancer (4). Canakinumab is an 
antibody that specifically targets IL-1B whereas the IL-1Ra inhibits both IL-1B and IL-
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1A, suggesting that IL-1A may play a role in growth of the primary tumor whereas IL-
1B is more prominent in driving the metastatic process.  
Previous reports have focused on the role of exogenous IL-1B in progression of 
metastasis.  Adding IL-1B to MCF7 cells in culture in the presence of EGF or TNFa1 
to MCF7 has been shown to promote EMT related changes the actin cytoskeleton 
(20,21) and induces an invasive phenotype (22). Our data are in agreement with 
these findings; tumor cells overexpressing IL-1B and IL-1R1 overexpressing cells 
stimulated with IL-1B have a more mesenchymal phenotype and exhibit molecular 
changes associated with EMT including reduced JUP; a molecule whose reduction is 
strongly associated with tumor cell shedding into the blood (23) (figure 2). However, 
we also show that in order to generate pro-metastatic effects, significantly higher 
doses of exogenous IL-1B are required to achieve the same pro-migratory effects, as 
endogenous IL-1B  (5ng/ml of exogenous IL-1B exerts similar invasive and migratory 
effects as 10-20pg/ml tumor derived IL-1B, supplementary figure 3), suggesting that 
IL-1B produced by the tumor cells is a more potent inducer of metastasis than 
exogenous sources. Spread of metastatic E0771 tumor cells from the primary site to 
bone or lung occurs in both IL-1B KO and control animals (figure 3f). These data, 
taken with the absence of a correlation between IL-1R1 in tumor cells with distant 
recurrence at any site (supplementary table 1) further imply that metastasis is 
stimulated by endogenous IL-1B from the tumor cells rather than exogenous sources 
of IL-1B acting upon the tumor cells.  
Recent work has demonstrated that IL-%SURPRWHV,/H[SUHVVLRQIURPȊį7FHOls 
causing expansion and polarisation of neutrophils in mammary tumors that in turn 
promotes metastasis (24). The authors hypothesised that IL-1B secreted from 
macrophages within the tumor is likely to be the key driver of this process. 
Canakinumab does not cross react with mouse IL-1B, and our in vivo models do not 
express T cells, therefore, although IL-1B positive neutrophils are likely to be an 
important tumor promoter, it is clear that tumor derived IL-1B also plays a key role in 
driving the metastatic process. Retrospective analysis of our data show that IL-1B 
positive immune cells were present at very low numbers in our patient samples and 
therefore it was not possible for us to investigate this hypothesis. However, patients 
who have IL-1B in their primary tumors and IL-1R1 in their tumor-associated stroma 
had increased breast cancer recurrence at distant sites. It is therefore likely that as 
well as promoting EMT, IL-1B from tumor cells interacts with cells from the local 
environment, including immune cells, promoting a metastasis-inducing environment.  
 19 
Once tumor cells leave their primary site they home to secondary metastatic organs. 
In breast cancer these are primarily bone, lung, and brain with bone being the most 
prominent (7). We have previously shown that a bone seeking breast cancer cell line, 
(MDA-IV) produces high concentrations of IL-1B compared to parental MDA-MB-231 
cells (2). Similarly, in a PC3 model of prostate cancer genetic overexpression of IL-
1B increased bone metastases from tumor cells injected into the heart whereas 
genetic knockdown of this molecule reduced bone metastasis (25). In keeping with 
this, our current study shows that breast cancer cells engineered to overexpress IL-
1B (MDA-MB-231-IL-1B+) have increased bone homing capabilities. Importantly, all 
of the models described above have been designed to investigate bone metastasis 
and although our data show a strong link between IL-1B expression and bone 
homing, it does not exclude IL-1B involvement in metastasis to other sites. 
Bone metastases occur when tumor cells are disseminated into the bone marrow 
and take up residence in the bone metastatic niche. This niche is thought to be made 
up of three interacting niches, the osteoblastic, vascular and hematopoietic stem cell 
niche (reviewed by (26,27)). There is increasing evidence from patient samples and 
model systems showing that stimulation of bone turnover and expansion of the bone 
metastatic niche promotes metastasis (8,12,13,16,28). Evidence for metastases in 
other organs predicts that proliferation of vascular endothelial cells and sprouting of 
new blood vessels may also promote proliferation of tumor cells in bone driving 
metastases formation (14,15,29).  We have previously shown that inhibiting IL-1R 
signalling with the IL-1R antagonist Anakinra prevents formation of overt metastasis 
from MDA-IV cells disseminated in bone by maintaining these cells in a state of 
dormancy (6). Recent evidence from mouse models of prostate cancer has also 
shown reduced bone metastasis from androgen receptor positive prostate cancer 
cells disseminated in bone following administration of Anakinra (30).  Shahriari et al. 
demonstrated that IL-1b secreted by prostate cancer cells generated cancer 
associated fibroblasts (CAFs) in the skeleton via upregulation of S100A4 and COX2 
(30). We have also demonstrated increased S100A4 in IL-1B overexpressing MDA 
IV breast cancer cells (2) and it is highly likely that IL-1B produced by tumor cells 
induces changes in mesenchymal stem cells leading to the generation of CAFs that 
in turn provide a supportive environment for the growth of cancer cells in bone. Our 
new data clearly show that anti-metastatic effects of Anakinra are not just due to 
reductions in CAFs but are due to inhibition of the activity of IL-1B on the bone 
metastatic niche. Inhibition of IL-1 signalling by treatments with Canakinumab, IL-
1Ra or genetic knock out of IL-1R1 in vivo reduced bone turnover and reduced blood 
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vessel length in the area of bone most commonly colonized by breast cancer cells 
(the trabecular region of the metaphysis) (12). This decreased blood vessel length is 
associated with decreased concentrations of endothelial cell growth factors 
endothelin 1 and VEGF (supplementary figure 3).  Therefore inhibiting IL-1B 
signalling may also reduce expansion of the metastatic niche by inhibiting neo-
vascularisation (31-33). We established that direct contact between tumor cells, 
primary human bone samples, bone marrow cells or osteoblasts promoted release of 
IL-1B from both tumor and bone cells (figure 4). Exogenous IL-1B did not increase 
tumor cell proliferation, even in cells overexpressing IL-1R1 (data not shown). 
Instead, IL-1B stimulated proliferation of bone marrow cells, osteoblasts and blood 
vessels induced proliferation of tumor cells (figure 4).  It is therefore likely that arrival 
of tumor cells expressing high concentrations of IL-1B will stimulate expansion of 
metastatic niche components and that contact between IL-1B expressing tumor cells 
and osteoblasts/blood vessels will drive tumor colonisation of bone. 
It is hypothesized that stimulation of osteoclast activity leading to increased bone 
resorption results in the release of growth factors into the local environment that in 
turn stimulates tumor growth (17). In vitro studies have previously reported that 
exposure of osteoclasts to IL-1B stimulates osteoclastogenesis (34) and our new 
data confirm that this also occurs in vivo (supplementary figure 6). Removal of IL-1B 
signalling in IL-1R1 KO mice or pharmacological inhibition of IL-1 signalling with IL-
1Ra or Canakinumab significantly reduces osteoclast activity. Interestingly, 
Canakinumab reduced osteoclast and osteoblast activity in mice bearing human 
bone implants, albeit to a lesser degree than Anakinra. Whether these effects are 
due to altered activity of osteoblasts and osteoclasts specifically in the human bone 
implants or direct effects of this human specific antibody on mouse bone remains to 
be established. Taken together, our data suggest that in addition to other 
mechanisms, IL-1B stimulated by tumor cell/bone cell interactions promotes 
osteoclast activity driving tumor progression at this site. Hence, inhibiting IL-1B 
reduces bone metastases by blocking this process. 
In conclusion, our data show that IL-1B is a novel biomarker that can be used to 
predict risk of breast cancer relapse. IL-1B activates different pro-metastatic 
mechanisms at the primary site compared with the metastatic site: Endogenous 
production of IL-1B by breast cancer cells promotes EMT, invasion, migration and 
organ specific homing. Once tumor cells arrive in the bone environment, contact 
between tumor cells and osteoblasts or bone marrow cells increased IL-1B secretion 
from all three-cell types. These high concentrations of IL-1B caused proliferation of 
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the bone metastatic niche and increased osteoclastic bone resorption stimulating 
growth of disseminated tumor cells into overt metastases (see supplementary figure 
7). These pro-metastatic processes were inhibited by administration of anti-IL-1B 
treatments. Therefore, targeting IL-1B with Canakinumab or an IL-1Ra may 
represent a novel therapeutic approach for breast cancer patients at risk of 
progressing to metastasis by preventing seeding of new metastases from established 
tumors and retaining tumor cells already disseminated in the bone in a state of 
dormancy. 
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 Figure 1. In vivo model of spontaneous human breast cancer metastasis to 
human bone predicts a key role for IL-1B signalling in breast cancer bone 
metastasis Two 0.5cm3 pieces of human femoral bone were implanted sub-
cutaneously into 8-week old female NOD SCID mice (n=10/group). 4-weeks later 
luciferase labelled MDA-MB-231-luc2-TdTomato or T47D cells were injected into the 
hind mammary fat pads.  Each experiment was carried out 3-separate times using 
bone form a different patient for each repeat. Histograms show fold change of IL-1B, 
IL-1R1, Caspase 1 and IL-1Ra copy number  (dCT) compared with GAPDH in tumor 
cells grown in vivo compared with those grown in a tissue culture flask (a i); 
mammary tumors that metastasise compared with mammary tumors tumors that do 
not metastasise (a ii); circulating tumor cells compared with tumor cells that remain in 
the fat pad (a iii) and bone metastases compared with the matched primary tumor (a 
iv). Fold change in IL-1B protein expression is shown in b) and fold change in copy 
number of genes associated with EMT (E-Cadherin, N-Cadherin and JUP) compared 
with GAPDH are shown in c) . * = P < 0.01** = P < 0.001, *** = P < 0.0001, ^^^ = P < 
0.001 compared with naïve bone 
Figure 2. Tumor-derived IL-1B induces epithelial to mesenchymal transition in 
vitro. MDA-MB-231, MCF7 and T47D cells were stably transfected with to express 
high levels of IL-1B, or scramble sequence (control) to assess effects of endogenous 
IL-1B on parameters associated with metastasis. Increased endogenous IL-1B 
resulted tumor cells changing from an epithelial to mesenchymal phenotype. Panel a) 
shows the morphology of MDA-MB-231 and MCF7 cells before and after stable 
transfection with IL-1B. Panel b) shows effects on proliferation of MDA-MB-231 and 
MCF7 cells over 70-72 hours. Panels c) and d) show fold change in copy number 
and protein expression of IL-1B, IL-1R1, E Cadherin, N Cadherin and JUP compared 
with GAPDH and B-Catenin, respectively. Ability of tumor cells to invade towards 
osteoblasts through Matrigel and/or 8uM pores are shown in d) and capacity of cells 
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to migrate over 24 and 48h is shown using a wound closure assay (e). Data are 
shown as mean +/- SEM, * = P < 0.01, ** = P < 0.001, *** = P < 0.0001. 
Figure 3. Tumor cell derived IL-1B promotes spontaneous metastasis and bone 
colonisation in vivo. In panels a and b, female NOD-SCID mice bearing two-0.5cm3 
pieces of human femoral bone received intra-mammary injections of MDA-MB-
231Luc2-TdTomato cells. Starting 1-week after tumor cell injection, mice were 
treated with 1mg/kg/day IL-1Ra, 20mg/kg/14-days Canakinumab, or placebo 
(control) (n=10/group). All animals were culled 8 weeks following tumor cell injection. 
Effects on primary tumor growth (a) and bone metastases (b) were assessed in vivo 
and immediately post-mortem by luciferase imaging and confirmed ex-vivo on 
histological sections. Data are shown as numbers of photons per second emitted 2 
minutes following sub-cutaneous injection of D-luciferin. In panels c-e 8-week old 
female BALB/c nude mice were injected with control (scramble sequence) or IL-1B 
overexpressing MDA-MB-231 IL-1B+, cells via the lateral tail vein. Tumor growth in 
bone and lung were measured in vivo by GFP imaging and confirmed ex-vivo on 
histological sections. Panel c) shows tumor growth in bone; d) shows representative 
uCT images of tumor bearing tibiae and the graph shows bone volume/tissue volume 
ratio indicating effects on tumor-induced bone destruction; e) shows numbers and 
size of tumors detected in lungs by each of the cell lines. Panel (f) shows 
spontaneous metastasis of E0771 cells from the 4th and 9th mammary glands to bone 
and lung in control and IL-1B KO mice. * = P < 0.01, ** = P < 0.001, *** = P < 0.0001. 
B = bone,  L = lung and tumor areas are indicated with arrows) 
Figure 4. Tumor cell-bone cell interactions stimulate IL-1B production and cell 
proliferation. MDA-MB-231 and T47D human breast cancer cell lines were cultured 
alone or in combination with live human bone, HS5 bone marrow cells or OB1 
primary osteoblasts. Panel a) shows the effects of culturing MDA-MB-231 or T47D 
cells in live human bone discs on IL-1B concentrations secreted into the media. The 
effect of co-culturing MDA-MB-231 or T47D cells with HS5 bone cells on IL-1B 
produced from the individual cell types following cell sorting and the proliferation of 
these cells are shown in b) and c). Effects of co-culturing MDA-MB-231 or T47D cells 
with OB1 (osteoblast) cells on proliferation are shown in e). Data are shown as mean 
+/- SEM, * = P < 0.01, ** = P < 0.001, *** = P < 0.0001. 
Figure 5. IL-1B in the bone microenvironment stimulates expansion of the bone 
metastatic niche. Effects of adding 40pg/ml or 5ng/ml recombinant IL-1B to MDA-
MB-231 or T47D breast cancer cells is shown in (a) and effects on adding 20pg/ml, 
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40pg/ml or 5ng/ml IL-1B on proliferation of HS5 (bone marrow cells) or OB1 
(osteoblasts), are shown in b) and c), respectively.  IL-1 driven alterations of the 
bone vasculature was measured following CD34 staining in the trabecular region of 
the tibiae from 10-12-week old female IL-1R1 knockout mice (d), BALB/c nude mice 
treated with 1mg/ml/day IL-1Ra for 31 days (e) and C57BL/6 mice treated with 10uM 
IL-1B neutralising antibody for 4-96h (f). Data are shown as mean +/- SEM, * = P < 
0.01, ** = P < 0.001, *** = P < 0.0001. 
Figure 6. Tumor derived IL-1B predicts future recurrence and bone relapse in 
patients with stage II and III breast cancer. 1189 primary breast cancer samples 
from patients with stage II and III breast cancer with no evidence of metastasis were 
stained for 17KD active IL-1B. Tumors were scored for IL-1B in the tumor cell 
population. Data shown are Cox model predicted curves, allowing for other Cox 
model-included variables such as number of involved lymph nodes, representing the 
correlation between tumor derived IL-1B and subsequent recurrence a) at any site or 
b) in bone over a 10-year time period.  
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